No Data
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Buy Recommendation for Biomea Fusion: Promising Clinical Developments of Icovamenib in Diabetes Treatment
Express News | Biomea Fusion Announces Approval of “Icovamenib” as International Nonproprietary Name for Bmf-219
Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
EF Hutton Initiates Coverage On Biomea Fusion With Buy Rating, Announces Price Target of $128